Spearhead Capital Advisors, LLC Exelixis, Inc. Transaction History

Spearhead Capital Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$17.44 - $23.16 $3,610 - $4,794	-207 Reduced 1.32%	15,462 $322,000
Q1 2022 Apr 28, 2022	BUY	$17.03 - $22.67 $266,843 - $355,216	15,669 New	15,669 $355,000
Q1 2021 Apr 28, 2021	SELL	$20.53 - $25.22 $252,724 - $310,458	-12,310 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$18.39 - $24.8 $13,130 - $17,707	714 Added 6.16%	12,310 $247,000
Q3 2020 Oct 16, 2020	BUY	$20.67 - $26.94 $15,543 - $20,258	752 Added 6.93%	11,596 $284,000
Q2 2020 Jul 16, 2020	BUY	$16.46 - $27.42 $178,492 - $297,342	10,844 New	10,844 $257,000

566

251M

1.45M

1.13M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.